Attached files

file filename
8-K - FORM 8-K - Shire plcdp82504_8k.htm

Exhibit 99.1

 

Press Release
www.shire.com  

 

 

Director/PDMR Shareholding

 

November 3, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG)

 

Notification of transactions by persons discharging managerial responsibilities

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Flemming Ornskov
2. Reason for the notification
a) Position / status Chief Executive Officer - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 100
d)

Aggregated information 

- Aggregated volume 

- Price 

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction

N/A

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Jeff Poulton
2. Reason for the notification
a) Position / status Chief Financial Officer - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 100
d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Joanne Cordeiro
2. Reason for the notification
a) Position / status Chief Human Resources Officer - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 52
d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Bill Mordan
2. Reason for the notification
a) Position / status General Counsel and Company Secretary - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 100
d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Perry Sternberg
2. Reason for the notification
a) Position / status Head of US Commercial - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 100
d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Kim Stratton
2. Reason for the notification
a) Position / status Head of International Commercial - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)

 

Identification code ISIN: JE00B2QKY057
b) Nature of the transaction

Automatic exercise of option over notional Ordinary Shares granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of Ordinary Shares.

 

(Details of related disposal of Ordinary Shares are referenced in section 5. below.)

 

c) Price(s) and volume(s) Price(s) Volume(s)
£31.41 296
d)

Aggregated information 

- Aggregated volume 

- Price 

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A
5. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)

 

Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Automatic disposal of Ordinary Shares related to the automatic option exercise referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the option exercise.

 

 

 

c) Price(s) and volume(s) Price(s) Volume(s)
£37.2071 14
d)

Aggregated information 

- Aggregated volume 

- Price 

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction London Stock Exchange (XLON)

 

 

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a) Name Matt Walker
2. Reason for the notification
a) Position / status Head of Technical Operations - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc American Depositary Shares (“ADSs”)
Identification code ISIN: US82481R1068
b) Nature of the transaction Automatic exercise of option over notional ADSs granted under the Shire Global Employee Stock Purchase Plan on November 1, 2016, and consequent receipt of ADSs.
c) Price(s) and volume(s) Price(s) Volume(s)
$123.90 100
d)

Aggregated information 

- Aggregated volume 

- Price 

N/A (single transaction)
e) Date of the transaction October 31, 2017
f) Place of the transaction N/A

 

 

 

Sarah Rixon 

Company Secretarial Assistant

 

For further information please contact:

 

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 203 549 0874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Katie Joyce kjoyce@shire.com   +1 781 482 2779

 

NOTES TO EDITORS

 

About Shire

 

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

 

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.

 

www.shire.com